ZNF667 and central nervous system cancer: Yuan et al. investigated both the diagnostic value and clinical significance of the ZNF667-AS1 expression in patients with glioma, and their findings suggest that ZNF667-AS1 could be used as a diagnostic and prognostic biomarker in glioma patients [37].